Clinical Trials
16 trialsNCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT05322850 2026-04-13
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Phase 1/2 Suspended
NCT06713837 2026-04-08
IMPACT-AML
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT07250217 2026-02-04
LAMME
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Phase NA Recruiting
NCT02932280 2025-12-05
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06667973 2025-03-12
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Not yet recruiting
NCT05348889 2025-02-13
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Chimagen Biosciences, Ltd
Phase 1/2 Terminated
NCT03151057 2024-03-12
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04033627 2022-09-29
TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
Shanghai Children's Medical Center
Phase NA Unknown
NCT03429387 2022-05-17
PIPPIN
Peter MacCallum Cancer Centre, Australia
Phase NA Completed
NCT03755947 2021-02-02
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Phase 2 Completed
NCT03185494 2019-04-17
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03312205 2019-01-09
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Unknown
NCT00788892 2018-01-12
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Jazz Pharmaceuticals
Phase 2 Completed
NCT00143975 2010-08-12
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
University of Ulm
Phase 2 Completed